Cumberland Pharmaceuticals to Announce 2025 Annual Financial Results & Company Update

Tuesday, Feb 24, 2026 4:06 pm ET1min read
CPIX--

Cumberland Pharmaceuticals will release its 2025 financial results and provide a company update on March 3, 2026. A conference call will be held at 4:30 p.m. Eastern Time to discuss the results. The company's portfolio includes FDA-approved brands such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia. Cumberland also has Phase II clinical programs underway for its ifetroban product candidate in patients with Systemic Sclerosis, Duchenne Muscular Dystrophy, and Idiopathic Pulmonary Fibrosis.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet